Pulse 2.0

Arcturus Meiji Investment Details

Cover art for Arcturus Meiji Investment Details

TL;DR: Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments. Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech. Meiji purchases Arcturus securities at $20.27 per share, an 80% premium, representing 7.9% of shares. Arcturus licenses ARCT-154 technology for an undisclosed therapeutic area.

Amit ChowdhryNov 17, 2026

From · · · 30s

TL;DR: Arcturus Meiji Investment Details

Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.

Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments. Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech. Meiji purchases Arcturus securities at $20.27 per share, an 80% premium, representing 7.9% of shares. Arcturus licenses ARCT-154 technology for an undisclosed therapeutic area.

  • Investment Terms
  • Technology License
  • Pandemic Partnership

Read the story version — the same reporting as a swipeable deck of 3 cards.

Read the original on Pulse 2.0

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on arcturus therapeutics and related topics.